Veeva Systems Inc. $VEEV Shares Sold by Aware Super Pty Ltd as trustee of Aware Super

Aware Super Pty Ltd as trustee of Aware Super lessened its stake in Veeva Systems Inc. (NYSE:VEEV) by 4.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 160,207 shares of the technology company’s stock after selling 8,182 shares during the quarter. Aware Super Pty Ltd as trustee of Aware Super owned about 0.10% of Veeva Systems worth $46,136,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in shares of Veeva Systems by 2.2% in the first quarter. Vanguard Group Inc. now owns 14,760,566 shares of the technology company’s stock valued at $3,418,990,000 after purchasing an additional 315,421 shares during the last quarter. Alliancebernstein L.P. increased its holdings in shares of Veeva Systems by 10.7% in the first quarter. Alliancebernstein L.P. now owns 5,499,651 shares of the technology company’s stock valued at $1,273,884,000 after purchasing an additional 532,269 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in shares of Veeva Systems by 0.7% in the first quarter. T. Rowe Price Investment Management Inc. now owns 5,203,867 shares of the technology company’s stock valued at $1,205,372,000 after purchasing an additional 34,169 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Veeva Systems by 20.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,992,372 shares of the technology company’s stock valued at $924,754,000 after purchasing an additional 689,700 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Veeva Systems by 7.5% in the first quarter. JPMorgan Chase & Co. now owns 3,230,758 shares of the technology company’s stock valued at $748,341,000 after purchasing an additional 225,125 shares during the last quarter. Institutional investors and hedge funds own 88.20% of the company’s stock.

Insider Transactions at Veeva Systems

In other news, insider Thomas D. Schwenger sold 3,350 shares of the firm’s stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $300.04, for a total transaction of $1,005,134.00. Following the completion of the transaction, the insider directly owned 23,773 shares in the company, valued at $7,132,850.92. This trade represents a 12.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Jonathan Faddis sold 14,595 shares of the firm’s stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $300.00, for a total value of $4,378,500.00. Following the transaction, the senior vice president owned 8,588 shares of the company’s stock, valued at approximately $2,576,400. This represents a 62.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 24,665 shares of company stock worth $7,438,000 over the last ninety days. Company insiders own 10.30% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on VEEV. Raymond James Financial reaffirmed an “outperform” rating and issued a $340.00 price target (up previously from $310.00) on shares of Veeva Systems in a report on Thursday, August 28th. Piper Sandler increased their price target on Veeva Systems from $325.00 to $355.00 and gave the company an “overweight” rating in a report on Thursday, August 28th. KeyCorp increased their price target on Veeva Systems from $285.00 to $325.00 and gave the company an “overweight” rating in a report on Monday, July 14th. Citigroup raised their target price on Veeva Systems from $329.00 to $349.00 and gave the stock a “buy” rating in a research note on Thursday, August 28th. Finally, Stifel Nicolaus raised their target price on Veeva Systems from $295.00 to $320.00 and gave the stock a “buy” rating in a research note on Thursday, August 28th. Sixteen research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Veeva Systems presently has a consensus rating of “Moderate Buy” and an average price target of $307.58.

Veeva Systems Stock Down 0.1%

VEEV stock opened at $287.40 on Thursday. The business has a fifty day moving average of $283.16 and a two-hundred day moving average of $265.92. The stock has a market cap of $47.11 billion, a price-to-earnings ratio of 59.02, a price-to-earnings-growth ratio of 2.22 and a beta of 0.98. Veeva Systems Inc. has a 52-week low of $201.54 and a 52-week high of $310.50.

Veeva Systems (NYSE:VEEV) last posted its earnings results on Wednesday, August 27th. The technology company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.90 by ($0.64). The business had revenue of $789.08 million for the quarter, compared to analyst estimates of $768.49 million. Veeva Systems had a return on equity of 13.72% and a net margin of 27.29%.Veeva Systems’s revenue was up 16.7% compared to the same quarter last year. During the same period last year, the business earned $1.62 EPS. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. As a group, sell-side analysts anticipate that Veeva Systems Inc. will post 4.35 EPS for the current year.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.